Diabetes treatment

Diabetes treatment comprises all nutritional, physical activity, pharmacological, insulin-based, educational, and, in selected patients, surgical interventions needed to control hyperglycemia and reduce the risk of acute and chronic complications. Modern treatment is not limited to lowering blood glucose, because it must consider the type of diabetes, disease duration, hypoglycemia risk, body weight, kidney function, cardiovascular disease, heart failure, frailty, patient preferences, adherence, costs, and tolerability. Treatment should therefore be constructed as a progressive pathway in which lifestyle changes, non-insulin medications, insulin, and metabolic procedures are integrated according to an individualized clinical rationale.

In type 1 diabetes, insulin therapy is essential from onset because autoimmune destruction of pancreatic beta cells causes absolute insulin deficiency. In type 2 diabetes, treatment arises from the interaction among insulin resistance, beta-cell dysfunction, excess weight, glucotoxicity, lipotoxicity, and cardiometabolic comorbidities. In this form, treatment selection no longer follows a simple glucose-centered sequence, but assesses early whether the patient has atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, or obesity, because some medication classes modify cardiorenal prognosis and body weight in addition to glycemic control.

The foundation of treatment is medical nutrition therapy and physical activity, because diet, movement, body composition, and insulin sensitivity directly affect pharmacological requirements. Medical nutrition therapy is not a standard diet identical for everyone, but a clinical prescription that must consider caloric intake, carbohydrate quality, meal distribution, protein content, dietary fats, fiber, alcohol, cultural preferences, working hours, hypoglycemia risk, and the presence of kidney disease, gastroparesis, or obesity. In type 2 diabetes, weight reduction in patients with excess weight improves insulin resistance, blood glucose, triglycerides, hepatic steatosis, blood pressure, and treatment requirements; in type 1 diabetes, nutrition must be coordinated with carbohydrate counting, insulin doses, and physical activity to avoid substantial glycemic fluctuations.

Physical exercise acts as a genuine metabolic intervention because it increases skeletal muscle glucose uptake, improves mitochondrial function, reduces visceral fat, attenuates insulin resistance, and contributes to blood-pressure and lipid control. Aerobic activity, resistance training, and reduction of sedentary behavior have complementary effects: aerobic exercise improves oxidative capacity, strength training preserves muscle mass and basal metabolism, and interrupting prolonged sitting reduces postprandial glycemic excursions. Exercise prescription must, however, be adapted to peripheral neuropathy, proliferative retinopathy, ischemic heart disease, hypoglycemia risk, insulin therapy, sulfonylureas, frailty, and functional independence.

When obesity and type 2 diabetes are closely intertwined, weight loss becomes a primary therapeutic objective rather than an ancillary element. The page on antidiabetic medications and obesity examines the role of classes that promote weight loss, particularly glucagon-like peptide 1 receptor agonists, dual incretin receptor agonists, and sodium-glucose cotransporter 2 inhibitors. In patients with severe obesity or difficult-to-control diabetes, metabolic surgery can profoundly alter the course of disease through caloric restriction, enteroendocrine changes, improved insulin sensitivity, increased incretin secretion, reduced lipotoxicity, and, in some patients, partial or complete remission of diabetes.

Antidiabetic medications include classes that differ greatly in site of action, glucose-lowering potency, effect on weight, hypoglycemia risk, cardiorenal impact, and safety profile. Some reduce hepatic glucose production, others increase insulin secretion, improve peripheral insulin sensitivity, delay intestinal carbohydrate absorption, enhance the incretin system, increase glycosuria, or act on multiple entero-pancreatic receptors. Selection should therefore not be based solely on glycated hemoglobin, but should integrate the clinical phenotype, risk of cardiovascular events, glomerular filtration, albuminuria, body weight, hypoglycemia risk, and specific contraindications.

Metformin has historically been the reference medication in type 2 diabetes, particularly when there are no renal or gastrointestinal contraindications or conditions that increase the risk of lactic acidosis. It acts mainly by reducing hepatic glucose production and improving insulin sensitivity, with a low risk of hypoglycemia and a neutral or mildly favorable effect on weight. Its role remains central, but it should not delay the introduction of medications with cardiovascular, renal, or weight benefits in patients who have specific indications for those classes.

Sulfonylureas and meglitinides are insulin secretagogues because they stimulate pancreatic beta cells to release insulin relatively independently of the current blood glucose level. Sulfonylureas have a longer duration of action and can effectively lower blood glucose, but increase the risk of hypoglycemia and weight gain, especially in older adults, kidney failure, irregular eating, or combination therapy. Meglitinides have a faster and shorter action, with greater emphasis on postprandial glucose control, but they also depend on residual beta-cell reserve and provide no specific cardiorenal benefits.

Thiazolidinediones, represented mainly by pioglitazone, improve insulin sensitivity through activation of the nuclear peroxisome proliferator-activated receptor gamma (PPAR-gamma). Their action involves adipose tissue, skeletal muscle, the liver, and metabolic inflammation, with potential utility in selected patients with marked insulin resistance and metabolic dysfunction-associated steatotic liver disease. Their clinical limitations are weight gain, fluid retention, edema risk, possible worsening of heart failure, fractures, and the need for careful patient selection.

DPP-4 inhibitors enhance the endogenous incretin effect by inhibiting degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). They provide a moderate glucose-lowering effect, low hypoglycemia risk when not combined with insulin or secretagogues, weight neutrality, and generally good tolerability. They are useful when simple, well-tolerated oral therapy is needed, but do not have the same effect on weight as GLP-1 receptor agonists or the same renal and heart-failure benefits as sodium-glucose cotransporter 2 inhibitors.

GLP-1 receptor agonists increase glucose-dependent insulin secretion, reduce glucagon, slow gastric emptying, and increase central satiety. This combination explains the reduction in blood glucose, weight loss, and, for some agents, cardiovascular protection documented in outcome trials. Dual incretin receptor agonists, such as tirzepatide, combine GIP receptor and GLP-1 receptor agonism, with high efficacy for glycated hemoglobin and body weight; their use nevertheless requires attention to gastrointestinal tolerability, titration, approved indications, and the overall clinical context.

SGLT2 inhibitors reduce renal glucose reabsorption in the proximal tubule, increasing urinary excretion of glucose and sodium. Their effect does not directly depend on insulin secretion, explaining the low risk of hypoglycemia as monotherapy. Beyond glycemic control, this class has assumed a central role in protection against heart failure and progression of chronic kidney disease, with benefits that in many settings exceed simple glycated hemoglobin reduction. Prescribing nevertheless requires assessment of glomerular filtration, risk of genital infections, euglycemic ketoacidosis, dehydration, hemodynamic status, and temporary discontinuation during fasting, surgery, or acute illness.

Alpha-glucosidase inhibitors, such as acarbose, act in the intestinal lumen by delaying digestion of complex carbohydrates and attenuating the postprandial glucose peak. Their effect is predominantly prandial and may be useful in phenotypes with post-meal hyperglycemia, especially when hypoglycemia and weight gain are to be avoided. Gastrointestinal tolerability often limits adherence because bloating, flatulence, and diarrhea result from colonic fermentation of unabsorbed carbohydrates.

Insulin therapy replaces or supplements endogenous insulin when beta-cell secretion is insufficient for metabolic requirements. In type 1 diabetes, it is life-saving and should reproduce physiological basal and prandial secretion as closely as possible. In type 2 diabetes, it is introduced when hyperglycemia remains substantial despite appropriate non-insulin therapy, when catabolic symptoms, marked glucotoxicity, unintentional weight loss, ketosis, pregnancy in specific settings, or contraindications to other medication classes are present. The goal is not only to lower blood glucose, but to ensure safety, flexibility, hypoglycemia prevention, and compatibility with diet and lifestyle.

Insulin regimens may include basal insulin, prandial boluses, correction doses, premixed insulin, insulin pumps, and automated insulin delivery systems, according to diabetes type, patient skills, glucose monitoring, and clinical risk. Basal insulin mainly controls hepatic glucose production during fasting and overnight, while rapid- or ultra-rapid-acting insulin covers carbohydrate absorption at meals and corrects intercurrent hyperglycemia. Titration should consider capillary glucose or continuous glucose monitoring sensors, glycated hemoglobin, nocturnal hypoglycemia, glycemic variability, physical activity, acute illness, kidney function, and the patient’s ability to recognize and treat hypoglycemia.

The main limitation of insulin is the need to balance efficacy and safety. An insufficient dose perpetuates glucotoxicity, polyuria, dehydration, weight loss, and the risk of ketoacidosis in insulin-deficient patients; an excessive dose causes hypoglycemia, weight gain, and fear of treatment. Insulin therapy therefore requires structured education, correct injection technique, site rotation, recognition of lipodystrophy, meal management, rules for physical activity and intercurrent illness, rational use of glucagon in patients at risk, and periodic review of glycemic goals.

Medication selection in type 2 diabetes should begin with the individual patient’s dominant problem. In the past, the therapeutic sequence was often built around metformin, progressive addition of other medications, and insulin in advanced stages. Today, treatment is earlier and phenotype-guided: the presence of atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, or obesity may direct selection toward specific medication classes independently of glycated hemoglobin alone. Metformin often remains part of treatment, but should not be viewed as an obligatory step when strong indications exist for medications with prognostic benefit.

In patients with clinically manifest atherosclerosis or high cardiovascular risk, the page on antidiabetic medications and cardiovascular risk explains why some GLP-1 receptor agonists and SGLT2 inhibitors have assumed a preferred role. GLP-1 receptor agonists with evidence of benefit reduce major cardiovascular events in selected populations, while SGLT2 inhibitors have a particularly important effect in preventing hospitalization for heart failure. In this setting, selection concerns not only glucose-lowering potency, but also the organ-protection profile, tolerability, weight, kidney function, and compatibility with other cardiovascular therapies.

In patients with diabetic kidney disease or reduced glomerular filtration, the page on antidiabetic medications and chronic kidney disease addresses selection according to estimated glomerular filtration, albuminuria, risk of kidney disease progression, hyperkalemia, heart failure, and the need for dose adjustment. SGLT2 inhibitors provide renal and cardiac protection in many patients with type 2 diabetes and chronic kidney disease, while GLP-1 receptor agonists may be added when additional glycemic control, weight reduction, or cardiovascular protection is needed. Metformin remains usable only within kidney-function limits and with appropriate monitoring, while secretagogues and insulin require caution because hypoglycemia risk rises as filtration declines.

In patients with obesity, medication selection should avoid, whenever possible, treatments that increase weight and insulin requirements without organ benefit, favoring strategies that reduce appetite, caloric intake, visceral fat, and cardiovascular risk. Medications with a favorable effect on weight do not replace nutrition and physical activity, but may make clinically meaningful weight loss more achievable. In patients with severe obesity, long-standing disease, multiple comorbidities, or poor control despite optimized treatment, metabolic surgery should be considered as an integrated therapeutic option rather than merely a cosmetic procedure or last resort.

The page on adverse effects and contraindications of antidiabetic medications is essential because the best theoretical treatment can become inappropriate if it does not respect the patient’s risk profile. Hypoglycemia is particularly relevant with insulin, sulfonylureas, and meglitinides; gastrointestinal effects are common with metformin, acarbose, GLP-1 receptor agonists, and dual incretin receptor agonists; SGLT2 inhibitors may promote genital infections, volume depletion, and, under predisposing conditions, euglycemic ketoacidosis; pioglitazone may cause edema, weight gain, and worsen heart failure. Treatment should therefore be reassessed according to adverse events, age, kidney function, comorbidities, diet, hospitalizations, surgery, and clinical changes.

Safety concerns not only individual medications, but also combinations. Combining medications with complementary mechanisms may improve efficacy and reduce the need for high doses, but some combinations are poorly rational or increase adverse-event risk. A GLP-1 receptor agonist and a DPP-4 inhibitor act on the same incretin axis and generally do not constitute a useful combination; insulin and secretagogues may increase hypoglycemia risk; diuretics, SGLT2 inhibitors, and hemodynamic frailty require attention to extracellular volume; kidney failure and older age require dose adjustment and less aggressive goals when risk exceeds benefit.

Therapeutic follow-up should integrate glycated hemoglobin, glycemic profiles, continuous glucose monitoring when indicated, weight, blood pressure, kidney function, albuminuria, lipids, hypoglycemia, adherence, injection technique, gastrointestinal tolerability, urinary or genital symptoms, nutritional status, and quality of life. Treatment personalization is a dynamic process: a medication that is appropriate at onset may become insufficient after progression of beta-cell dysfunction, and treatment suitable for a young adult may become excessively risky in a frail patient, one with kidney disease, or one with impaired awareness of hypoglycemia. Diabetes treatment should therefore be recalibrated periodically, maintaining the goals of reducing complications, preserving organ function, and making treatment sustainable in real life.